Anika Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Anika Therapeutics

09/08/2023 24:11

* Anika Therapeutics Inc  ANIK.OQ  reported a quarterly
adjusted
loss of 19 cents​​ per share for the quarter ended in June. The
mean expectation of two analysts for the quarter was for a loss
of 27 cents per share.
    * Revenue rose 11.7% to $44.30 million from a year ago;
analysts
expected $40.56 million. 
    * Anika Therapeutics Inc's reported EPS for the quarter was
a loss
of 19 cents​.
    * The mean earnings estimate of analysts had risen by
about 8.5%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Anika Therapeutics Inc shares had fallen by 19.0% this
quarter and lost 28.9% so far this year.
    * The company reported a quarterly loss of $2.74 million.
    * Wall Street's median 12-month price target for Anika
Therapeutics Inc is $33.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 8 at 11:11 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.27          -0.19          Beat
 Mar. 31 2023      -0.30          -0.47          Missed
 Dec. 31 2022      -0.24          -0.34          Missed
 Sep. 30 2022      -0.25          -0.15          Beat